Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
TGTX

TG Therapeutics Inc

TGTX

15.72USD-0.31 (-1.93%)Market Closed
Watchlist

Market Summary

USD15.72-0.31
Market Closed
-1.93%

TGTX Alerts

  • Big jump in Revenue (Y/Y)

TGTX Stock Price

View Fullscreen

TGTX RSI Chart

TGTX Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-13.82

Price/Sales (Trailing)

12.79

Price/Free Cashflow

-34.46

TGTX Price/Sales (Trailing)

TGTX Profitability

Return on Equity

-614.42%

Return on Assets

-85.41%

Free Cashflow Yield

-2.9%

TGTX Fundamentals

TGTX Revenue

Revenue (TTM)

189.8M

Revenue Y/Y

174.4K%

Revenue Q/Q

931.57%

TGTX Earnings

Earnings (TTM)

-175.7M

Earnings Y/Y

-17.53%

Earnings Q/Q

-21.36%

Price Action

Last 7 days

25.1%

Last 30 days

48.0%

Last 90 days

54.3%

Trailing 12 Months

92.9%

How does TGTX drawdown profile look like?

TGTX Financial Health

Current Ratio

2.93

TGTX Investor Care

Shares Dilution (1Y)

4.19%

Diluted EPS (TTM)

-0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20238.6M24.1M189.8M0
20227.9M7.0M5.0M2.8M
2021907.0K2.4M4.4M6.7M
2020152.0K152.0K152.0K152.0K
2019337.0K152.0K152.0K152.0K
2018224.8K297.5K370.3K443.0K
2017283.1K240.5K231.5K152.0K
2016229.4K290.5K322.5K323.0K
201586.9K118.8K150.7K182.6K
201436.9K42.9K49.0K55.0K
201353.5K87.5K120.6K30.8K
201200019.0K
20110000
20100000

Latest Insider Trading transactions for TGTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 28, 2023
hoberman kenneth
acquired
-
-
20,000
-
Sep 28, 2023
echelard yann
acquired
-
-
20,000
-
Sep 28, 2023
lonial sagar
sold
-
-
-20,000
-
Sep 28, 2023
hume daniel
acquired
-
-
20,000
-
Sep 28, 2023
charney laurence n
acquired
-
-
20,000
-
Aug 11, 2023
weiss michael s
bought
1,013,000
10.13
100,000
ceo and president
Jun 23, 2023
lonial sagar
sold
-814,538
23.37
-34,854
-
Jun 02, 2023
power sean a
sold
-1,966,370
26.7
-73,647
chief financial officer
Mar 12, 2023
power sean a
acquired
-
-
85,000
chief financial officer
Mar 12, 2023
weiss michael s
acquired
-
-
985,000
ceo and president

1–10 of 50

Which funds bought or sold TGTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
Raleigh Capital Management Inc.
added
5.41
-18,673
10,266
-%
Dec 06, 2023
CITIGROUP INC
added
117
-1,337,530
3,622,700
-%
Nov 30, 2023
Neo Ivy Capital Management
sold off
-100
-375,000
-
-%
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-2.51
-1,601,380
781,969
-%
Nov 22, 2023
Graham Capital Management, L.P.
new
-
159,383
159,383
-%
Nov 21, 2023
Walleye Capital LLC
new
-
745,486
745,486
-%
Nov 21, 2023
COMERICA BANK
new
-
3,904
3,904
-%
Nov 21, 2023
Walleye Trading LLC
added
309
21,861
79,713
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
added
56.04
-3,066,220
3,390,970
0.02%
Nov 16, 2023
Financial Gravity Asset Management, Inc.
reduced
-88.00
-127
25.00
-%

1–10 of 34

Latest Funds Activity

Are funds buying TGTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TGTX
No. of Funds

Schedule 13G FIlings of TG Therapeutics Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 03, 2023
darwin global management, ltd.
7.1%
10,451,241
SC 13G
Feb 09, 2023
vanguard group inc
10.67%
15,502,764
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 03, 2023
state street corp
7.17%
10,415,161
SC 13G/A
Feb 01, 2023
blackrock inc.
6.3%
9,132,890
SC 13G/A
Jul 11, 2022
fmr llc
-
0
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 01, 2022
blackrock inc.
6.2%
8,902,165
SC 13G/A
Feb 16, 2021
great point partners llc
0.0%
0
SC 13G/A
Feb 10, 2021
ra capital management, l.p.
6.4%
8,685,471
SC 13G/A

Recent SEC filings of TG Therapeutics Inc

View All Filings
Date Filed Form Type Document
Nov 06, 2023
10-Q
Quarterly Report
Nov 01, 2023
8-K
Current Report
Sep 29, 2023
4
Insider Trading
Sep 29, 2023
4
Insider Trading
Sep 29, 2023
4
Insider Trading
Sep 29, 2023
4
Insider Trading
Sep 29, 2023
4
Insider Trading

Peers (Alternatives to TG Therapeutics Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
30.9B
-
5.25% 401813.88%
-3.6K
218.4K
- -102.45%
30.5B
10.7B
8.54% -55.34%
-8.79
2.86
-53.67% -129.46%
22.2B
1.7B
4.15% -23.37%
-43.62
12.9
79.37% 56.87%
17.9B
2.3B
11.05% -8.44%
121.62
7.74
15.05% 75.21%
12.4B
3.6B
0.84% -34.33%
29.1
3.43
8.35% -51.49%
MID-CAP
7.6B
272.9M
35.37% 34.74%
-12.51
27.78
141.38% 4.43%
5.9B
-
14.36% 263.35%
-10.02
48.33
54.84% -12.96%
3.6B
631.9M
-7.32% 48.57%
-24.01
5.65
23.54% 31.53%
3.3B
223.4M
11.28% -10.13%
-16.47
14.87
- -26.24%
2.6B
240.7M
-10.83% -25.35%
-12.82
10.93
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
11.36% -14.92%
24.59
4.38
81.69% -7.29%
656.6M
1.0B
-22.00% -67.89%
-1.2
0.63
-43.15% 58.48%
100.5M
6.4M
- -79.23%
-0.61
15.6
-44.11% 50.48%
39.5M
-
376.67% 112.17%
-0.61
-
- -29.23%
23.3M
-
25.24% 3980.68%
-0.49
-
- -13.74%

TG Therapeutics Inc News

Latest updates
Stocks Register07 Dec 202304:31 pm31 hours ago
Investing.com UK06 Dec 202307:43 pm2 days ago
InvestorsObserver06 Dec 202307:21 pm2 days ago
Investing.com UK06 Dec 202303:48 pm2 days ago
Yahoo Finance04 Dec 202301:46 pm4 days ago
Nasdaq01 Dec 202309:00 pm7 days ago
Defense World28 Nov 202309:59 am10 days ago
Simply Wall St24 Nov 202310:55 am14 days ago
InvestorsObserver10 Nov 202308:00 am28 days ago
Seeking Alpha07 Nov 202308:00 am31 days ago
Yahoo Finance06 Nov 202308:00 am32 days ago
Yahoo Finance03 Nov 202307:00 am35 days ago
Marketscreener NL01 Nov 202311:30 am37 days ago

Financials for TG Therapeutics Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue931.6%165,815,00016,074,0007,803,00080,00095,000594,0002,016,0002,321,0002,030,0001,545,000793,00038,00038,00038,00038,00038,00038,00038,00038,00038,00038,000
Operating Expenses-100.0%-60,748,00044,795,00052,143,00035,057,00039,535,00068,888,00095,269,00087,158,00079,036,00089,995,00086,820,00085,760,00050,883,00050,283,00037,998,00060,899,00035,582,00034,727,00054,188,00034,366,000
  S&GA Expenses6.7%32,769,00030,715,00028,068,00022,505,00014,254,00012,638,00020,609,00032,412,00034,899,00034,017,00026,762,00043,859,00035,296,00014,434,00014,261,0007,055,5002,914,0002,716,0002,342,0001,912,500968,000
  R&D Expenses-47.5%14,753,00028,122,00015,870,00029,635,00020,801,00026,874,00048,042,00062,646,50051,967,00044,871,00063,094,00042,961,00050,464,00036,449,00036,022,00030,943,50057,985,00032,866,00032,385,00052,275,50033,398,000
EBITDA Margin-------48.84-43.15-51.16---300-1,796-1,091-1,092-1,099-1,10222.6013.944.77--
Interest Expenses2.4%3,713,0003,627,0002,844,0002,862,0001,648,0003,017,0002,664,0001,079,0001,038,0001,623,0001,898,0001,290,5001,610,0002,228,0001,201,0001,899,0001,537,0001,077,000774,000220,000221,000
EBT Margin-------50.01-44.00-52.04---308-1,838-1,137-1,137-1,137-1,137-1.14-1.14-0.57--
Net Income100.0%--47,610,000-39,232,000-52,994,000-35,818,000-40,510,000-69,013,000-93,338,500-85,637,000-78,497,000-90,628,000-88,218,000-87,163,000-52,884,000-51,116,000-39,572,500-61,930,000-36,212,000-35,156,000-53,860,000-33,951,000
Net Income Margin----60.52-71.22-48.98-41.44-41.26-52.04-77.84-142-351-1,838-1,517-1,351-1,242-1,137-----
Free Cashflow----59,905,000-23,873,000-34,499,000-49,116,000-68,696,000-86,989,000-67,280,000-60,344,000-81,422,000-52,181,000-56,621,000-43,879,000-62,183,000-30,427,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets49.9%33122119719421825230338041048154962627429510216393.0010711884.00114
  Current Assets53.0%31920918516818320324233137245553561226028188.0014980.0094.0010579.00110
    Cash Equivalents56.9%15297.0061.0010211014718630032740247255325426152.0011445.0057.0064.0043.0071.00
  Inventory11.0%34.0030.0027.00------------------
  Net PPE-35.4%0.000.000.000.000.000.001.001.001.001.000.000.000.000.000.000.000.000.000.000.000.00
  Goodwill0%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities-7.8%16618017013511712313314298.0098.0010310610310010312411993.0098.0060.0043.00
  Current Liabilities-20.6%58.0073.0063.0053.0036.0043.0055.0065.0088.0088.0092.0088.0078.0068.0063.0084.0080.0056.0061.0039.0040.00
    LT Debt, Current--------1.0016.0023.0030.0022.0015.007.00-------
    LT Debt, Non Current1.2%99.0098.0097.0071.0070.0069.0067.0067.00---8.0015.0022.0029.0029.0029.0029.0028.00--
Shareholder's Equity-100.0%-40.0027.0059.00100129170237312383445519171194-39.00-13.0019.0024.0072.00
  Retained Earnings7.1%-1,500-1,613-1,566-1,527-1,500-1,400-1,400-1,328-1,200-1,100-1,100-980-892-805-752-701-661600-563-528-474
  Additional Paid-In Capital0.6%1,6651,6541,5941,5861,5751,5671,5681,5661,5471,5331,5171,5001,0631,000751740636613583553546
Shares Outstanding0.3%15115114914614513513414313213213214111910910588.0090.0084.0081.0075.0074.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations299.3%83,704-42,005-59,902-23,870-34,495-49,116-68,689-86,909-67,201-60,169-81,355-52,026-56,532-43,834-62,115-30,393-33,202-35,860-33,351-33,690-33,009
  Share Based Compensation-26.8%9,18412,5416,82311,0687,000-1,0002,10014,35614,00016,30016,61833,52128,3007,40011,0685,6212,0751,7571,8821,458-173
Cashflow From Investing-199.1%-30,22930,501-6,16816,269-2,99010,379-43,6713,288-631-2,475-514-52,07614,91111,2051,4504.00-44.00457-1,135238-6,435
Cashflow From Financing-99.1%42147,04725,23849.00275135-85055,997-7,361-7,162-55.00403,38935,265241,09281.0098,35420,69528,28456,8804,6944,492

TGTX Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Revenue$ 165,815$ 94$ 189,691$ 2,705
Costs and expenses:    
Cost of revenue3,50926,277262
Research and development:    
Noncash compensation2,9153,24910,1627,471
Other research and development11,83817,55248,58188,246
Total research and development14,75320,80158,74395,717
Selling, general and administrative:    
Noncash compensation6,2693,74018,386663
Other selling, general and administrative26,50010,51473,16746,840
Total selling, general and administrative32,76914,25491,55347,503
Total costs and expenses51,03135,057156,573143,482
Operating income (loss)114,784(34,963)33,118(140,777)
Other expense (income):    
Interest expense3,7131,64810,1847,329
Other income(2,859)(793)(4,154)(2,765)
Total other expense (income), net8548556,0304,564
Net income (loss)$ 113,930$ (35,818)$ 27,088$ (145,341)
Net income (loss) per common share:    
Basic (in dollars per share)$ 0.8$ (0.26)$ 0.19$ (1.08)
Diluted (in dollars per share)$ 0.73$ (0.26)$ 0.19$ (1.08)
Weighted-average shares outstanding:    
Basic (in shares)142,871,227135,327,035141,571,785134,839,207
Diluted (in shares)155,871,749135,327,035145,952,913134,839,207
Product [Member]    
Revenue:    
Revenue$ 25,068$ 56$ 48,868$ 2,591
License [Member]    
Revenue:    
Revenue$ 140,747$ 38$ 140,823$ 114

TGTX Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 150,902$ 102,304
Short-term investment securities78,25759,374
Accounts receivable, net39,3200
Inventories33,5530
Prepaid research and development5,0014,237
Other current assets12,0812,359
Total current assets319,114168,274
Restricted cash1,2821,273
Long-term investment securities012,404
Right of use assets8,2718,888
Leasehold interest, net1,4681,627
Equipment, net133307
Goodwill799799
Total assets331,067193,572
Current liabilities:  
Accounts payable and accrued expenses39,74142,019
Other current liabilities1,2171,017
Lease liability – current portion1,4791,581
Deferred revenue - current portion6,903152
Accrued compensation8,3388,432
Total current liabilities57,67853,201
Deferred revenue, non-current portion190305
Loan payable – non-current98,90871,135
Lease liability – non-current9,52210,344
Total liabilities166,298134,985
Commitments and contingencies
Stockholders’ equity:  
Common stock, $0.001 par value per share (175,000,000 shares authorized, 151,490,731 and 146,426,697 shares issued, 151,449,422 and 146,385,388 shares outstanding at September 30, 2023 and December 31, 2022, respectively)151146
Additional paid-in capital1,664,7971,585,708
Treasury stock, at cost, 41,309 shares at September 30, 2023 and December 31, 2022(234)(234)
Accumulated deficit(1,499,945)(1,527,033)
Total stockholders’ equity164,76958,587
Total liabilities and stockholders’ equity$ 331,067$ 193,572
TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
 CEO
 WEBSITEwww.tgtherapeutics.com
 EMPLOYEES244

TG Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for TG Therapeutics Inc? What does TGTX stand for in stocks?

TGTX is the stock ticker symbol of TG Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TG Therapeutics Inc (TGTX)?

As of Thu Dec 07 2023, market cap of TG Therapeutics Inc is 2.43 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TGTX stock?

You can check TGTX's fair value in chart. The fair value of TG Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TG Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TGTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TG Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TGTX is over valued or under valued. Whether TG Therapeutics Inc is cheap or expensive depends on the assumptions which impact TG Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TGTX.

What is TG Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, TGTX's PE ratio (Price to Earnings) is -13.82 and Price to Sales (PS) ratio is 12.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TGTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on TG Therapeutics Inc's stock?

In the past 10 years, TG Therapeutics Inc has provided 0.152 (multiply by 100 for percentage) rate of return.